Inclusion Criteria:

- Platinum-resistant (recurrence within 6 months of a platinum-containing regimen) or
platinum refractory (progression while on platinum) disease.

- Measurable disease as defined by RECIST v1.0 criteria on screening testing

- Be ≥18 years of age at the time of registration for protocol therapy.

- Give written, informed consent for participation in the protocol.

- Must consent to correlative blood sample collections.

- Be at least 4 weeks from last treatment to allow recovery from prior toxicity to a
Grade 1 or less.

- The following exceptions are allowed: hormonal therapy - 1 week wash-out; radiation
therapy - 3 week wash-out; weekly chemotherapy - 3 week wash-out

- Patients coming off experimental therapy with biological agents not expected to cause
myelotoxicity should have been off treatment for at least 4 weeks as wash-out period

- Negative serum pregnancy test within 14 days prior to the study entry and be
practicing an effective form of contraception if hysterectomy and/or oophorectomy was
not part of the prior treatment

Exclusion Criteria:

- Prior therapy with pegylated liposomal doxorubicin or doxorubicin.

- Prior therapy with BIBF 1120.

- Prior anti-angiogenic therapy with tyrosine kinase inhibitors (e.g. sorafenib,
sunitinib, others). Note: Prior therapy with bevacizumab is allowed, provided that at
least 3 months have elapsed since the last dose of bevacizumab.

- Grade 2 or greater neuropathy, at time of registration.

- Active cancer within the last 5 years, with the exception of superficial skin cancer
(basal cell or squamous cell skin carcinoma), carcinoma in situ of the cervix, Stage
I endometrial cancer with less than 50% invasion of the myometrium, or other
adequately treated Stage I or II cancer in complete remission.

- Presence of active infection requiring antibiotic treatment, at time of registration.

- Presence of uncontrolled serious medical condition or psychiatric illness as
determined by the treating physician, at time of registration.

- Known history of immune deficiency and be receiving combination anti-retroviral
therapy

- Known or clinically manifest brain metastases, as progressive neurologic dysfunction
may develop, that would confound the evaluation of neurologic and other adverse
events.

- Presence of gastrointestinal disorders or abnormalities that would influence the
absorption of the study drug.

- Presence of uncontrolled hypertension, arrhythmia, congestive heart failure or
angina, at time of registration. Patients who have had a myocardial infarction or
cardiac surgery should be at least 6 months from the event and free of active
symptoms.

- Serious illness or concomitant non-oncological disease such as neurologic,
psychiatric, infection disease or laboratory abnormality that may increase the risk
associated with study participation or study drug administration.

- Major injuries within the past 4 weeks prior to start of study treatment with
incomplete wound healing and/or planned surgery during the on-treatment study period.

- History of clinically significant hemorrhagic or thromboembolic event in the past 6
months